Publication | Closed Access
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
76
Citations
0
References
2009
Year
Surgical OncologyCancer ManagementPathologyPharmacotherapyMay 30Second-line TreatmentOncologyMetronomic TherapyClinical TrialsClinical OncologyRadiation OncologyCancer ResearchFinal TextRadiologyHealth SciencesDocetaxel Versus DocetaxelCancer TreatmentLung CancerBronchial NeoplasmMedicine
CRA8003 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]